Given the shared mutations between skeletal dysplasia associated with FGFR3 and FGFR3-dependent cancers like urothelial carcinomas, cervical carcinomas, and multiple myeloma, some therapeutic strategies of ACH have been co-opted conceptually from the oncological field. This evidence concerns the gene FGFR3 and cervical carcinoma.